Search Results - "Boers, M"

COSMIN Risk of Bias tool to assess the quality of studies on reliability or measurement error of outcome measurement instruments: a Delphi study by Mokkink, L B, Boers, M, van der Vleuten, C P M, Bouter, L M, Alonso, J, Patrick, D L, de Vet, H C W, Terwee, C B

“…Scores on an outcome measurement instrument depend on the type and settings of the instrument used, how instructions are given to patients, how professionals…”
Get full text

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update by Smolen, Josef S, Landewé, Robert, Bijlsma, Johannes, Burmester, Gerd, Chatzidionysiou, Katerina, Dougados, Maxime, Nam, Jackie, Ramiro, Sofia, Voshaar, Marieke, van Vollenhoven, Ronald, Aletaha, Daniel, Aringer, Martin, Boers, Maarten, Buckley, Chris D, Buttgereit, Frank, Bykerk, Vivian, Cardiel, Mario, Combe, Bernard, Cutolo, Maurizio, van Eijk-Hustings, Yvonne, Emery, Paul, Finckh, Axel, Gabay, Cem, Gomez-Reino, Juan, Gossec, Laure, Gottenberg, Jacques-Eric, Hazes, Johanna M W, Huizinga, Tom, Jani, Meghna, Karateev, Dmitry, Kouloumas, Marios, Kvien, Tore, Li, Zhanguo, Mariette, Xavier, McInnes, Iain, Mysler, Eduardo, Nash, Peter, Pavelka, Karel, Poór, Gyula, Richez, Christophe, van Riel, Piet, Rubbert-Roth, Andrea, Saag, Kenneth, da Silva, Jose, Stamm, Tanja, Takeuchi, Tsutomu, Westhovens, René, de Wit, Maarten, van der Heijde, Désirée

“…Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large…”
Get more information

Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting by Thomas, K.S., Apfelbacher, C.A., Chalmers, J.R., Simpson, E., Spuls, P.I., Gerbens, L.A.A., Williams, H.C., Schmitt, J., Gabes, M., Howells, L., Stuart, B.L., Grinich, E., Pawlitschek, T., Burton, T., Howie, L., Gadkari, A., Eckert, L., Ebata, T., Boers, M., Saeki, H., Nakahara, T., Katoh, N.

“…Summary Background The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema (AE) clinical…”
Get full text

A systematic review of the influence of rice characteristics and processing methods on postprandial glycaemic and insulinaemic responses by Boers, Hanny M., Seijen ten Hoorn, Jack, Mela, David J.

“…Rice is an important staple food for more than half of the world's population. Especially in Asian countries, rice is a major contributor to dietary glycaemic…”
Get full text

EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases by Duru, N, van der Goes, M C, Jacobs, J W G, Andrews, T, Boers, M, Buttgereit, F, Caeyers, N, Cutolo, M, Halliday, S, Da Silva, J A P, Kirwan, J R, Ray, D, Rovensky, J, Severijns, G, Westhovens, R, Bijlsma, J W J

“…To develop recommendations for the management of medium to high-dose (ie, >7.5 mg but ≤100 mg prednisone equivalent daily) systemic glucocorticoid (GC) therapy…”
Get more information

Differences in descriptions of Kellgren and Lawrence grades of knee osteoarthritis by Schiphof, D, Boers, M, Bierma-Zeinstra, S M A

“…Correct application of the Kellgren and Lawrence (K&L) classification system is difficult due to inexact wording of the descriptors. We summarised different…”
Get more information

The COBRA trial 20 years later by Boers, M

“…This article provides a perspective on the immediate and follow-up results of the COBRA trial that compared the combination of step-down prednisolone,…”
Get full text

Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation by van Halm, V P, Peters, M J L, Voskuyl, A E, Boers, M, Lems, W F, Visser, M, Stehouwer, C D A, Spijkerman, A M W, Dekker, J M, Nijpels, G, Heine, R J, Bouter, L M, Smulders, Y M, Dijkmans, B A C, Nurmohamed, M T

“…Patients with rheumatoid arthritis (RA) have an increased cardiovascular risk, but the magnitude of this risk is not known precisely. A study was undertaken to…”
Get more information

Dutch–Flemish translation of 17 item banks from the Patient-Reported Outcomes Measurement Information System (PROMIS) by Terwee, C. B., Roorda, L. D., de Vet, H. C. W., Dekker, J., Westhovens, R., van Leeuwen, J., Cella, D., Correia, H., Arnold, B., Perez, B., Boers, M.

“…Background The Patient-Reported Outcomes Measurement Information System (PROMIS®) is a new, state-of-the-art assessment system for measuring patient-reported…”
Get full text

Towards developing diagnostic criteria for early knee osteoarthritis: data from the CHECK study by Runhaar, J, Kloppenburg, M, Boers, M, Bijlsma, J W J, Bierma-Zeinstra, S M A

“…Abstract Objectives There is a general consensus that a shift in focus towards early diagnosis and treatment of knee OA is warranted. However, there are no…”
Get full text

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases by Hoes, J N, Jacobs, J W G, Boers, M, Boumpas, D, Buttgereit, F, Caeyers, N, Choy, E H, Cutolo, M, Da Silva, J A P, Esselens, G, Guillevin, L, Hafstrom, I, Kirwan, J R, Rovensky, J, Russell, A, Saag, K G, Svensson, B, Westhovens, R, Zeidler, H, Bijlsma, J W J

“…Objective:To develop evidence-based recommendations for the management of systemic glucocorticoid (GC) therapy in rheumatic diseases.Methods:The…”
Get full text

The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agents by Boers, M

“…Most registration trials in rheumatoid arthritis (RA) include a placebo arm in the setting of an incomplete response to disease-modifying antirheumatic…”
Get more information

Validation of two PROMIS item banks for measuring social participation in the Dutch general population by Terwee, C. B., Crins, M. H. P., Boers, M., de Vet, H. C. W., Roorda, L. D.

“…Background The Patient-Reported Outcomes Measurement Information System (PROMIS) item banks ‘Ability to Participate in Social Roles and Activities’ (35 items)…”
Get full text

Is it time to revisit the role of ultrasound in rheumatoid arthritis management? by D'Agostino, M A, Boers, M, Wakefield, R J, Emery, P, Conaghan, P G

“…For over a decade, a large number of studies have highlighted the benefits of ultrasound (US) in the diagnosis and management of rheumatic diseases, especially…”
Get more information

Patients’ and rheumatologists’ perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis—an international survey within the GLORIA study by Santiago, T, Voshaar, M, de Wit, M, Carvalho, P D, Buttgereit, F, Cutolo, M, Paolino, S  , Castelar Pinheiro, G R, Boers, M, Da Silva, J A P

“…Abstract Objective To evaluate the current perspectives of patients and health professionals regarding the efficacy and safety of low-dose glucocorticoids…”
Get full text

Short-term placebo response in trials of patients with symptomatic osteoarthritis: differences between hip and knee by Reiter-Niesert, S, Boers, M, Detert, J

“…Summary Background In placebo-controlled RCT of symptomatic treatment in osteoarthritis (OA) the extent of pain reduction is heterogeneous, the pooled effect…”
Get full text

Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study by Bos, W H, Wolbink, G J, Boers, M, Tijhuis, G J, de Vries, N, van der Horst-Bruinsma, I E, Tak, P P, van de Stadt, R J, van der Laken, C J, Dijkmans, B A C, van Schaardenburg, D

“…Anti-citrullinated protein antibodies (ACPA) are associated with increased risk for rheumatoid arthritis. To investigate the effect of the presence and levels…”
Get more information

Effects of glucocorticoids on radiological progression in rheumatoid arthritis by Kirwan, J R, Bijlsma, J W J, Boers, M, Shea, B J

“…Glucocorticoid use in rheumatoid arthritis (RA) is widespread. Two Cochrane Reviews have been published examining the short term clinical benefit of low dose…”
Get more information

Genotypic and Phenotypic Characterization of Replication-Competent HIV-2 Isolated from Controllers and Progressors by Lungu, Cynthia, Overmars, Ronald J, Grundeken, Esmée, Boers, Patrick H M, van der Ende, Marchina E, Mesplède, Thibault, Gruters, Rob A

“…Although some individuals with HIV-2 develop severe immunodeficiency and AIDS-related complications, most may never progress to AIDS. Replication-competent…”
Get full text

Prediction of final infarct volume from native CT perfusion and treatment parameters using deep learning by Robben, David, Boers, Anna M.M., Marquering, Henk A., Langezaal, Lucianne L.C.M., Roos, Yvo B.W.E.M., van Oostenbrugge, Robert J., van Zwam, Wim H., Dippel, Diederik W.J., Majoie, Charles B.L.M., van der Lugt, Aad, Lemmens, Robin, Suetens, Paul

“…•Prediction of the final infarct volume in acute ischemic stroke patients.•Takes into account the baseline CTP images and the time and treatment…”
Get full text